fedratinib acts as a competitive inhibitor of protein kinase jak 2 with ic 6 nm related kinases flt3 and ret are also sensitive with ic 25 nm and ic 17 nm respectively significantly less activity was observed against other tyrosine kinases including jak3 ic 169 nm in treated cells the inhibitor blocks downstream cellular signalling jak stat leading to suppression of proliferation and induction of apoptosis i was approved by fda on 16 august 2019 myelofibrosis is a myeloid malignancy associated with anemia splenomegaly and constitutional symptoms patients with myelofibrosis frequently harbor jak stat activating mutations that are sensitive to tg101348 phase i trial results focused on safety and efficacy of fedratinib in patients with high or intermediate risk primary or post polycythemia vera essential thrombocythemia myelofibrosis have been published in 2011 fedratinib was originally discovered at targegen in 2010 sanofi aventis acquired targegen and continued development of fedratinib until 2013 in 2016 impact biomedicines acquired the rights to fedratinib from sanofi and continued its development for the treatment of myelofibrosis and polycythemia vera in january 2018 the drug s rights were transferred to celgene with their purchase of impact biomedicines